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ABSTRACT: Few secondary metabolites have been reported
from mammalian microbiome bacteria despite the large numbers
of diverse taxa that inhabit warm-blooded higher vertebrates. As a
means to investigate natural products from these microorganisms,
an opportunistic sampling protocol was developed, which focused
on exploring bacteria isolated from roadkill mammals. This
initiative was made possible through the establishment of a newly
created discovery pipeline, which couples laser ablation electro-
spray ionization mass spectrometry (LAESIMS) with bioassay
testing, to target biologically active metabolites from microbiome-
associated bacteria. To illustrate this process, this report focuses
on samples obtained from the ear of a roadkill opossum
(Dideiphis virginiana) as the source of two bacterial isolates
(Pseudomonas sp. and Serratia sp.) that produced several new and known cyclic lipodepsipeptides (viscosin and serrawettins,
respectively). These natural products inhibited bioﬁlm formation by the human pathogenic yeast Candida albicans at
concentrations well below those required to inhibit yeast viability. Phylogenetic analysis of 16S rRNA gene sequence libraries
revealed the presence of diverse microbial communities associated with diﬀerent sites throughout the opossum carcass. A putative
biosynthetic pathway responsible for the production of the new serrawettin analogues was identiﬁed by sequencing the genome
of the Serratia sp. isolate. This study provides a functional roadmap to carrying out the systematic investigation of the genomic,
microbiological, and chemical parameters related to the production of natural products made by bacteria associated with non-
anthropoidal mammalian microbiomes. Discoveries emerging from these studies are anticipated to provide a working framework
for eﬀorts aimed at augmenting microbiomes to deliver beneﬁcial natural products to a host.
During the past decade, the ﬁeld of human microbiomescience has undergone a revolution. A key component of
this transformation is the realization that the human body’s
endogenous microbial ﬂora do not live as an isolated
community, but instead function within a dynamic human−
microbe network.1−4 There is also growing appreciation that
the proper function of the human microbial ecosystem plays an
important role in forestalling disease and maintaining good
health.3 The extent of the interconnectedness between humans
and their microbiomes has even led some to refer to it as “our
second genome”.5
As the scientiﬁc community’s understanding of the human
microbiome’s composition has matured, so have the research
questions that are being posed concerning the microbiome’s
roles in health and disease. Whereas initial inquiries in the ﬁeld
focused on resolving fundamental problems such as, “what is
there?” and “what do they do?” microbiome researchers are
beginning to ask new questions such as, “how can we control
their function?” Emerging eﬀorts to engineer or manipulate
human microbiomes oﬀer exciting opportunities to restore and
potentially enhance human health and performance.
There are two general approaches that provide feasible
options for engineering human microbiomes. The ﬁrst tactic
involves the introduction or elimination of selected microbial
taxa from the host.6−8 This approach was successfully tested in
animal models of inﬂammatory bowel disease,9−11 arthritis,12
colon cancer,13 cystic ﬁbrosis,14 and depression,15 resulting in
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Figure 1. Overview of the combined microbiological, chemical, and genomic steps employed to investigate microbiome bacteria derived from
roadkill mammals for new natural products and their biosynthetic gene clusters. The methodologic approach illustrated here was developed to
support the discovery of new bioactive natural products from non-anthropoidal sources, which in turn could be used for the purpose of engineering
new biosynthetic pathway functions into the microbiomes of both humans and agriculturally important animals.
Figure 2. Summary of the bacterial isolates collected from roadkill mammals. (A) Breakdown of the 3659 roadkill microbiome isolates based on the
source organisms from which they were derived. (B) Distribution of the isolates based on the locations/oriﬁces on the carcasses from which they
were derived. (C) Categorization of the isolate data illustrating the percent contribution of each body site to the overall bacterial collection prepared
from the diﬀerent animal species (note that the colors and categories used to construct the slices within each of the pie charts in panel C are the
same as those used for the pie chart in panel B).
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the restoration of disease-free phenotypes. This method was
also eﬀectively used in humans to restore resilience against
Clostridium dif f icile colonization.16,17 A second approach that
presents a more structured form of microbiome engineering
involves genetically modifying selected microorganisms to
provide them new functions that may beneﬁt a host.7,18−20
These methods could include the (i) introduction of new
metabolic enzymes that are absent in the host and its
microbiome consortia or (ii) incorporation of new small-
molecule-generating biosynthetic genes that are responsible for
the production of biomolecules not currently made in
humans.21 One can envision the potential for generating and
applying designer microbes that produce compounds capable of
warding oﬀ selected pathogens or modulating disease processes.
In pursuit of identifying candidate biosynthetic gene clusters
whose products might beneﬁt humans, our team investigated
natural products made by bacteria from non-anthropoidal
mammalian hosts. While several unique metabolites have been
previously reported from bacteria inhabiting humans,20,22−25
relatively little is known about the chemicals generated by
bacteria colonizing the majority of other mammals.26−28
Accordingly, we developed a bioassay-based pipeline that oﬀers
the opportunity to detect natural products with potentially
beneﬁcial therapeutic attributes (Figure 1). The rationale
behind our approach was that natural products derived from
other mammalian species may have arisen through adaptive
host-mediated selection, and these compounds might be
biomedically useful, as well as relatively safe.
To obtain the large number of microbiome bacteria from
diverse mammalian sources that we required for our screening
process, we used an opportunistic sampling approach to explore
roadkill (animals killed as a result of unintentional vehicular
collisions), which is an underutilized source of microbiome
bacteria.29 In our case, we focused on fresh (recently deceased)
roadkill comprising mammals that are native or naturalized to
central Oklahoma. Roadkill oﬀers a convenient route to
accessing microbiome bacteria since it (i) is abundant in
many areas, (ii) presents the opportunity for sampling diverse
animals and their associated bacteria across a broad geo-
graphical region, (iii) alleviates concerns over the trapping and
testing of live animals since only carcasses are sampled, and (iv)
oﬀers the possibility to conduct chronologically dependent
testing of speciﬁc animal populations over extended peri-
ods.29,30 In this paper, we present the development and
application of our mammalian-microbiome-derived natural
product discovery pipeline (Figure 1) and present data for
several new and known depsipeptides obtained from opossum-
associated bacteria. The compounds were detected based on
their abilities to inhibit Candida albicans bioﬁlm formation,
which is the single most prevalent cause of human fungal
infections.
■ RESULTS AND DISCUSSION
Opportunistic sampling of mammalian roadkill took place over
a two-year period near the University of Oklahoma campus
(Norman, OK, USA). Carcasses deemed fresh (generally
determined to have been struck by motor vehicles no more
than 10 h prior to sampling) were selected, and those with one
or more intact oriﬁces (i.e., mouth, nose, ear, eye, and rectum)
or gastrointestinal tracts were sampled roadside with sterile
swabs. The mammalian roadkill carcasses that were sampled
included (in order of increasing frequency) the following:
skunk (Mephitis mephitis), armadillo (Dasypus novemcinctus),
deer (Odocoileus virginianus), raccoon (Procyon lotor), squirrel
(Sciurus carolinensis), and opossum (Dideiphis virginiana).
Sampling of these carcasses led to the generation of 3659
bacterial isolates (Figure 2). Not only were opossum carcasses
the most frequently encountered, they were also a particularly
rich source of morphologically unique bacteria, accounting for
39% (1425) of the roadkill-associated isolates collected (Figure
2).
The phylogenetic diversity of the opossum microbiome was
further evaluated by sequencing 16S rRNA gene libraries.
Swabs taken from ﬁve opossum body sites were used to
generate 13 994 sequences, which clustered into 73 operational
taxonomic units (OTUs) at 97% sequence similarity (Figure 3).
Members of the Gammaproteobacteria dominated the
communities from the mouth, nose, and ear, constituting
greater than 90% of each community. The upper gastro-
intestinal tract also contained a sizable population of
Gammaproteobacteria (72.4%) and Bacilli (21.7%). The
rectum was notably more diverse containing large populations
of Fusobacteria (47.2%), Clostridia (19.1%), and Bacteroidia
(10.8%). The Gammaproteobacteria were largely represented
by two abundant operational taxonomic units, one of which was
Figure 3. Phylogenetic diversity of mammalian microbiome bacteria from diﬀerent oriﬁces/body sites of a roadkill opossum carcass.
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unclassiﬁed and another assigned most closely to the genus
Pseudomonas.
All of the bacterial isolates were individually cultured in two
or more broth media, and a library of their ethyl-acetate-soluble
natural products was prepared. These samples were subjected
to bioassay screening against several medically relevant targets.
One of the opossum ear samples showed appreciable activity in
an assay designed to identify compounds that inhibited C.
albicans bioﬁlm formation. However, upon closer scrutiny, this
sample was determined to be derived from a culture containing
two bacteria that each produced slightly diﬀerent-sized white,
opaque, mucoidal colonies. When the two microorganisms
were obtained in pure culture, the 16S rRNA genes of both
isolates were sequenced, and the bacteria were identiﬁed as
members of the genera Pseudomonas and Serratia. Representa-
tive colonies of both isolates were analyzed in situ by laser
ablation electrospray ionization mass spectrometry (LAE-
SIMS). A single major metabolite was observed from the
Pseudomonas sp. (Figure 4), which was determined to be
viscosin (1) based on its MS/MS fragmentation pattern relative
to an authentic standard. Its assignment was later conﬁrmed by
a single-crystal X-ray diﬀraction experiment of the metabolite
following its scale-up production and puriﬁcation (Figure 5).
LAESIMS analysis of the Serratia sp. isolate led to the
puriﬁcation of serrawettin W2 (2), as well as three co-
metabolites that could not be dereplicated (i.e., m/z values and
fragmentation patterns did not produce any reasonable matches
to reported bacterial natural products). Although the
information derived from the LC-MS investigation of the
compounds (MS data, LC retention times, and UV−vis PDA
Figure 4. Targeting microbial natural products using LAESIMS. The inset shows bacterial colonies growing on the surface of an agar plate. The plate
was placed inside of the LAESIMS chamber for mass spectrometry proﬁling. A subset of representative colonies was selected (indicated by red
arrows), and a virtual grid was laid over these colonies using the instrument’s software to target where laser ablation would occur. The light blue
polygons show where mass data were collected from the colonies within the range of m/z 200−2000. The presented mass data were derived from
the circled colony (average of several locations taken from the colony and subtracted from mass data obtained from a blank [uncolonized] portion of
the plate), which reveals prominent single and doubly charged sodium adduct ions for viscosin (1).
Figure 5. ORTEP rendering of viscosin (1) illustrating the metabolite’s absolute conﬁguration (determined by reﬁnement of the Flack parameter;
the water molecule identiﬁed near atom N2 has been removed from the ﬁgure for clarity; however, the position of the water can be found in the
Supporting Information). The numbering system used for this structure reﬂects the atom assignments used in the Supporting Information and in the
Cambridge Structural Database (CCDC 1511786).
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proﬁles) enabled us to postulate that the Serratia sp.
metabolites were analogues of 2, we decided to pursue their
scale-up puriﬁcation for structure conﬁrmation and bioactivity
testing.
Upon partitioning of the liquid cultures of the Serratia sp.
isolate, the combined ethyl acetate layer was determined to
retain the putative serrawettin analogues, as well as the bioﬁlm
inhibition activity. LAESIMS-guided fractionation of the
organic layer by HP20SS VLC, as well as preparative and
semipreparative C18 HPLC resulted in the puriﬁcation of
compounds 3−5, along with 2, whose structure was
subsequently conﬁrmed by MS experiment, 1H and 13C NMR
data (Tables 1 and 2, respectively), and Marfey’s analysis.31,32
Analysis of HRESIMS data for compound 3 provided a
prominent ion with m/z 740.4235 [M + Na]+ that supported a
molecular formula of C37H59N5O9. This indicated that
compound 3 likely diﬀered from 2 by the loss of a CH2 unit.
Comparative analysis of the 1H−1H TOCSY data for 3 versus 2
revealed that the spin system associated with the isoleucine
residue was altered. Inspection of the 1H (Table 1) and 1H−1H
dqfCOSY NMR data for 3 showed that the amide proton (8.28,
d, J = 7.22, 1 H) coupled with the α-proton (3.73, t, J = 7.76,
7.76, 1 H), which coupled to a methine (1.95, m, 2 H) that in
turn coupled with methyl protons (0.84, m, 6 H). These results
could be accounted for if the isoleucine residue in 2 changed to
a valine residue in 3. Subsequent investigation of the metabolite
by hydrolysis followed by Marfey’s analysis conﬁrmed that the
isoleucine residue was no longer present and instead an L-valine
had been incorporated. Thus, metabolite 3 was assigned the
trivial name serrawettin W4 in recognition of its structural
relationship to metabolite 2.
A similar structure determination strategy was applied to
compound 4 after observing that the HRESIMS data contained
a prominent ion with m/z 726.4073 [M + Na]+, which
corresponded to a molecular formula of C36H57N5O9. This
indicated that the metabolite was deﬁcient for two CH2 units
relative to compound 2. Inspection of the 1H−1H TOCSY data
for 4 provided strong evidence that metabolites 2 and 4 shared
identical macrocycles. This was supported by hydrolysis
followed by Marfey’s analysis, which conﬁrmed the presence
of the same amino acid residues in 2 and 4. Turning our
attention to the MSn result, as well as 1H NMR data attributable
to the hydrocarbon chain, it was determined that the lipid-
derived portion of 4 was missing two CH2 units relative to 2.
With the structure of metabolite 4 conﬁrmed, the new
compound was given the trivial name serrawettin W5.
An evaluation of metabolite 5 by HRESIMS provided an ion
with m/z 770.4346 [M + Na]+ that enabled us to determine its
molecular formula was C38H61N5O10. This represented an
increase of one oxygen atom in 5 relative to compound 2.
Focusing on the 1H NMR data (Table 1) for the amino acid
portion of the macrocycle in 5, it was readily apparent that the
aromatic protons associated with the phenylalanine residue in 2
were altered and that one hydrogen bonded to a carbon was
missing. The new aromatic spin-coupled network appeared as
an AA′BB′ system, which led us to propose that 5 incorporated
a tyrosine residue in place of the phenylalanine in 2. The
assignments of the carbon and hydrogen spins for the tyrosine
were subsequently conﬁrmed by HMBC experiment, as well as
hydrolysis followed by Marfey’s analysis, which together
established the presence of an L-tyrosine in 5. Metabolite 5
was assigned the trivial name serrawettin W6.
With the stereochemical assignments of the amino acid
residues completed, we focused on securing the conﬁgurations
of the C-3 positions in each compound. Applying biosynthetic-
based logic to the problem, it appeared reasonable to presume
that the stereochemistries of the metabolites’ C-3 positions
were set upon incorporation of either 3-hydroxydecanoic acid
(2, 3, and 5) or 3-hydroxyoctanoate (4). A survey of the
chemical literature concerning the spectroscopic properties of
β-hydroxy fatty acids revealed a decisive trend in their chiral-
optical data (Table S1). Namely, in chloroform, R-conﬁgured
β-hydroxy fatty acids displayed consistent levorotatory
activities, whereas in ethanol, these molecules exhibited
dextrorotatory properties. Returning to the acid hydrolysates
prepared from 2−5, we were able to purify milligram quantities
of enantiopure β-hydroxy fatty acids from each sample. Speciﬁc
rotation values were obtained for the products in both ethanol
and chloroform, which enabled us to assign R conﬁgurations to
the C-3 positions in 2−5.
The genome of the Serratia sp. isolate was sequenced to link
the identiﬁed natural products to their prospective biosynthetic
gene cluster. Over 5.4 million reads were generated and
assembled into 35 contiguous sequences after quality control.
The annotated 16S rRNA gene was extracted and aligned to
OTUs classiﬁed as Gammaproteobacteria, which we had
observed from the opossum ears. These showed close (98%)
homology to an OTU classiﬁed as a member of the
Enterobacteriaceae. A total of eight potential secondary-
metabolite-producing biosynthetic gene clusters were identiﬁed
by antiSMASH analysis, including four NRPS clusters. One of
the candidate clusters presented a near-perfect match to what
was required to construct metabolites 2−5 (SI Figure S69).
Journal of Natural Products Article
DOI: 10.1021/acs.jnatprod.6b00772
J. Nat. Prod. 2017, 80, 598−608
602
The puriﬁed compounds were evaluated for their abilities to
inhibit growth and bioﬁlm production of C. albicans. None of
the metabolites were able to kill fungal cells at concentrations
up to 100 μM. Compound 1 from the Pseudomonas sp. isolate
proved to be the most potent inhibitor of C. albicans bioﬁlm
formation, with an IC50 value of 4.6 ± 1.0 μM. The Serratia sp.
metabolites exhibited a range of bioﬁlm inhibition capabilities,
with 2 being the most potent (IC50 = 7.7 ± 0.7 μM), followed
by 4 (IC50 = 13.4 ± 0.2 μM), 5 (IC50 = 29.2 ± 0.4 μM), and 3
(IC50 = 59.8 ± 5.7 μM). The abilities of these bacterial cyclic
lipodepsipeptides to limit bioﬁlm formation, while not
impacting yeast cell survival, hint at the possibility of alternative
chemical options for controlling C. albicans infections by means
of bioﬁlm modulation.
The use of opportunistic sampling to humanely investigate
the microbiomes of a broad range of animals oﬀers an
intriguing method to accelerate the exploration of this resource
for new natural products. Notably, the discovery pipeline
Table 1. 1H NMR Data (600 MHz, DMSO-d6) for Serrawettins W2 (2), W4, (3), W5 (4), and W6 (5)
serrawettin W2 (2) serrawettin W4 (3) serrawettin W5 (4) serrawettin W6 (5)
position δH, m (J in Hz) δH, m (J in Hz) δH, m (J in Hz) δH, m (J in Hz)
Lipid (3R)-hydroxydecanoic acid (3R)-hydroxydecanoic acid (3R)-hydroxyoctanoic acid (3R)-hydroxydecanoic acid
2a 2.36, dd (5.9,14.4) 2.38, dd (6.8, 14.6) 2.35, dd (6.2, 14.5) 2.34, dd (5.4, 14.2)
2b 2.63, dd (3.3, 14.6) 2.59, dd (3.1, 14.7) 2.63, dd (3.1, 14.4) 2.66, m
3 4.92, m 4.96, m 4.93, d (7.3) 4.91, m
4 1.52, m 1.53, m 1.52, m 1.53, d (7.4)
5 1.23, m 1.22, m 1.24, m 1.23, m
6 1.23, m 1.22, m 1.24, m 1.23, m
7 1.23, m 1.22, m 1.24, m 1.23, m
8 1.23, m 1.22, m 0.81, m 1.23, m
9 1.23, m 1.22, m 1.23, m
10 0.82, m 0.84, m 0.82, m
Residue 1 D-leucine D-leucine D-leucine D-leucine
11 (NH) 7.81, d (8.7) 7.86, d (8.5) 7.82, d (8.6) 7.86, d (8.8)
12 4.35, ddd (3.9, 8.7, 12.0) 4.39, m 4.35, ddd (3.8, 8.6, 10.1) 4.36, m
13a 1.13, m 1.22, m 1.13, m 1.23, m
13b 1.42, m 1.44, m 1.42, m 1.45, m
14 1.64, m 1.63, m 1.64, m 1.65, dd (5.3, 10.8)
15 0.82, m 0.84, m 0.81, m 0.82, m
16 0.82, m 0.84, m 0.81, m 0.82, m
Residue 2 L-serine L-serine L-serine L-serine
18 (NH) 8.07, d (8.5) 8.09, d (7.9) 8.18, d (8.6) 8.24, d (7.4)
19 4.41, m 4.39, m 4.42, m 4.43, m
20a 3.55, m 3.59, m 3.58, m 3.59, m
20b 3.62, m
21 (OH) 5.02, t (5.5) 5.04, m 5.08, s 5.13, s
Residue 3 L-threonine L-threonine L-threonine L-threonine
23 (NH) 8.01, d (8.4) 8.01, d (7.8) 8.16, d (8.2) 8.24, d (7.4)
24 4.1, dd (3.0, 8.3) 4.03, dd (3.6, 7.9) 4.07, dd (3.0, 8.4) 4.09, dd (2.9, 8.4)
25 4.24, m 4.16, m 4.20, s 4.23, s
26 (OH) 5.09, d (4.7) 5.09, d (5.0) 5.18, s 5.24, d (5.3)
27 0.97, d (6.4) 0.94, d (6.3) 0.96, d (6.4) 0.98, d (6.5)
Residue 4 D-phenylalanine D-phenylalanine D-phenylalanine D-tyrosine
29 (NH) 7.44, d (7.0) 7.59, d (7.2) 7.46, d (7.0) 7.41, d (6.9)
30 4.44, dd (4.7, 7.2, 7.3) 4.39, m 4.42, m 4.36, m
31a 2.88, dd (7.3, 13.8) 2.88, dd (8.1, 13.8) 2.88, dd (7.4, 13.8) 2.79, dd (7.3, 13.8)
31b 3.12, dd (4.6, 13.9) 3.15, dd (4.2, 13.9) 3.11, dd (4.6, 13.9) 2.98, dd (4.6, 13.8)
33 7.14, m 7.14, m 7.14, d (6.8) 6.84, d (8.1)
34 7.06, m 7.14, m 7.06, d (7.0) 6.53, d (8.1)
35 CH, 7.14, m CH, 7.14, m CH, 7.14, d (6.8) OH, 5.32, m
36 7.06, m 7.14, m 7.06, d (7.0) 6.53, d (8.1)
37 7.14, m 7.14, m 7.14, d (6.8) 6.84, d (8.1)
Residue 5 L-isoleucine L-valine L-isoleucine L-isoleucine
39 (NH) 8.47, d (6.6) 8.28, d (7.2) 8.44, d (6.7) 8.48, br s
40 3.76, m 3.73, t (7.8) 3.77, m 3.76, m
41 1.76, m 1.95, m 1.76, m 1.76, m
42a 1.13, m (CH3) 0.84, m 1.13, m 1.12, m
42b 1.36, m 1.35, m 1.35, m
43 0.82, m 0.81, m 0.82, m
44 0.82, m 0.84, m 0.81, m 0.82, m
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presented here is an enabling tool for identifying bacterial
natural products from nonhominid mammals. Our approach,
however, is not without limitations. One potential concern
centers on how well our collection strategy accurately reﬂects
the native microbiomes of living mammals since the micro-
biomes of humans are known to change as the time since death
increases.33 While our investigation did not test this point
speciﬁcally, we did make eﬀorts to sample only recently
deceased mammals and took care to avoid oriﬁces that were
markedly compromised by collisions with vehicles. Therefore,
we remain conﬁdent that the isolates obtained in this study are
representative members of mammalian microbiomes and not
taxa simply derived from the immediate environment or strictly
enhanced via decomposition. Further studies are anticipated to
provide additional microbiome-associated bacteria, their natural
products, and associated biosynthetic gene clusters, which
might serve as candidates for future microbiome engineering
endeavors. Indeed, colony proﬁling by LAESIMS suggests the
presence of many bacteria-derived peptide-like products that we
anticipate will possess potentially useful therapeutic properties.
■ EXPERIMENTAL SECTION
Procedures. NMR data were obtained on Varian VNMR
spectrometers (Agilent Technologies, Inc., Santa Clara, CA, USA)
with broadband and triple resonance probes at 25 ± 0.5 °C unless
otherwise noted. Optical rotation measurements were made on a
Rudolph Research Autopol III automatic polarimeter (Rudolph
Research Analytical Corp., Hackettstown, NJ, USA). UV data were
measured with a Hewlett-Packard 8452A diode array spectropho-
Table 2. 13C NMR Data (150 MHz, DMSO-d6) for Serrawettins W2 (2), W4, (3), W5 (4), and W6 (5)
serrawettin W2 (2) serrawettin W4 (3) serrawettin W5 (4) serrawettin W6 (5)
position δC, type δC, type δC, type δC, type
Lipid (3R)-hydroxydecanoic acid (3R)-hydroxydecanoic acid (3R)-hydroxyoctanoic acid (3R)-hydroxydecanoic acid
1 169.2, C 168.8, C 169.2, C 168.5, C
2 40.6, CH2 39.9, CH2 40.5, CH2 40.6, CH2
3 72.2, CH 71.6, CH 72.1, CH 72.1, CH
4 32.4, CH2 32.1, CH2 32.3, CH2 32.4, CH2
5 31.5, CH2 31.1, CH2 24.8, CH2 31.5, CH2
6 29.0, CH2 28.4, CH2 31.3, CH2 29.2, CH2
7 28.8, CH2 22.0, CH2 22.2, CH2 29.2, CH2
8 22.5, CH2 24.7, CH2 14.2, CH3 22.5, CH2
9 21.4, CH2 22.0, CH2 25.2, CH2
10 14.4, CH3 13.9, CH3 14.4, CH3
Residue 1 D-leucine D-leucine D-leucine D-leucine
12 51.1, CH 50.6, CH 51.1, CH 51.2, CH
13 40.8, CH2 40.4, CH2 40.8, CH2 40.6, CH2
14 24.2, CH 23.8, CH 24.2, CH 24.2, CH
15 23.8, CH3 21.2, CH3 21.4, CH3 21.4, CH3
16 23.8, CH3 23.3, CH3 23.8, CH3 23.7, CH3
17 171.7, C 172.2, C 172.6, C 170.3, C
Residue 2 L-serine L-serine L-serine L-serine
19 57.1, CH 56.5, CH 57.2, CH 57.2, CH
20 61.6, CH2 61.1, CH2 61.7, CH2 61.6, CH
22 172.5, C 170.6, C 171.0, C 171.8, C
Residue 3 L-threonine L-threonine L-threonine L-threonine
24 58.8, CH 58.8, CH 59.0, CH 58.9, CH
25 65.8, CH 65.5, CH 65.9, CH 65.9, CH
27 20.6, CH3 20.1, CH3 20.6, CH3 20.6, CH3
28 171.0, C 169.7, C 170.0, C 169.2, C
Residue 4 D-phenylalanine D-phenylalanine D-phenylalanine D-tyrosine
30 54.0, CH 54.0, CH 54.1, CH 54.3, CH
31 37.6, CH2 37.0, CH2 37.6, CH2 36.9, CH2
32 137.2, C 137.1, C 139.3, C 126.6, C
33 128.5, CH 128.0, CH 128.5, CH 130.4, CH
34 129.5, CH 129.1, CH 129.5, CH 115.4, CH
35 126.9, CH 126.3, CH 126.8, CH 156.5, C
36 129.5, CH 129.1, CH 129.5, CH 115.4, CH
37 128.5, CH 128.0, CH 128.5, CH 130.4, CH
38 169.9, C 171.0, C 171.6, C 170.7, C
Residue 5 L-isoleucine L-valine L-isoleucine L-isoleucine
40 58.0, CH 59.4, CH 58.0, CH 58.0, CH
41 35.0, CH 28.9, CH 35.0, CH 34.9, CH
42 25.2, CH2 19.1, CH3 25.2, CH2 25.2, CH2
43 10.6, CH3 10.6, CH3 10.5, CH3
44 15.7, CH3 18.9, CH3 15.7, CH3 15.8, CH3
45 171.0, C 170.6,C 171.1, C 171.1, C
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tometer (Agilent Technologies, Inc.). IR spectra were obtained on a
Bruker Vector 22 FT-IR spectrometer (Bruker Corp., Billerica, MA,
USA). Accurate mass electrospray-ionization mass spectrometry data
were collected on an Agilent 6538 High-Mass-Resolution QTOF mass
spectrometer (Agilent Technologies, Inc.). HPLC separations were
carried out on a Shimadzu system using a SCL-10A VP controller
(Shimadzu Scientiﬁc Instruments Inc., Columbia, MD, USA) and
Gemini 5 μm C18 and hexyl-phenyl columns (110 Å, 250 × 21.2 mm
and 250 × 10.0 mm, respectively, Phenomenex Inc., Torrance, CA,
USA) with ﬂow rates of 10 or 4 mL/min. All chemicals and solvents
used in the study were of research grade quality or better.
Opportunistic Sampling. A 48 km section of Oklahoma State
Highway 9 from the University of Oklahoma campus, Norman, OK, to
the city of Tecumseh, OK, was used for this study. This route was
chosen because it traverses a state park (Lake Thunderbird State
Park), a signiﬁcant quantity of acreage devoted to agriculture, and
forested land, which are all prime habitats for many of Oklahoma’s
major mammalian species. Additionally, the highway is heavily traveled
(a major east−west thoroughfare from Arkansas to Texas) with posted
speed limits of 65 mph (105 kph). The juxtaposition of having an
active highway that intersects such a variety of mammalian habitats
made this a prime location for near daily animal−vehicle collisions.
A sampling permit was obtained from the State of Oklahoma
(Scientiﬁc Collector Permit #5250), and the University of Oklahoma
IACUC was informed of the experiments, resulting in the assignment
of an internal case-tracking number (R11-021). When fresh roadkill
was encountered (generally less than 10 h old), the intact oriﬁces,
which included the mouth, ear, nose, and rectum, were sampled with
sterile cotton-tipped swabs and then immediately plunged into sterile
phosphate-buﬀered saline (PBS) buﬀer. When opportunities presented
themselves, samples were also taken by swabbing the inner portions of
the lower gastrointestinal tract.
Isolation and Cultivation of Bacteria. Sample swabs were
generally processed within 1−2 h after collection. The cotton tips of
the swabs were placed into 1.0 mL of PBS and vortexed. These
suspensions were diluted 10−3 with PBS, and 50 μL aliquots were
spread onto three types of solid agar media (10% tryptic soy agar, 10%
brain heart infusion agar, and DM7 agar) and incubated at 30 °C for 3
days. Colonies were targeted for isolation based on their
morphological uniqueness. Colony picking was performed using
sterile toothpicks and the inoculum used to prepare streak plates on
DM7 medium. Single colonies were picked with toothpicks, which
were then dipped into tryptic soy broth containing 15% glycerol and
incubated at room temperature for 1 week. Cultures of isolates were
used to generate samples for cryogenic preservation at −80 °C, as well
as inoculate various media for further chemical and bioassay studies.
For these experiments, 5 μL aliquots were inoculated into the wells of
three 24-well plates containing 50% tryptic soy broth, 50% brain heart
infusion broth, and DM7 broth and incubated for 7 days at 30 °C.
These cultures were subjected to partitioning three times against equal
volumes of ethyl acetate. The organic layers from each sample were
combined, and the solvent was removed in vacuo. Extracts were
evaluated for bioactivities, and those determined to be active were
examined by LCMS and LAESIMS.
Strain Information. The Serratia sp. and Pseudomonas sp. isolates
were obtained from swabbing the ear canal of a roadkill opossum
encountered on Oklahoma State Highway 9 near Norman, OK. While
the original colony selected for the study was thought to be a single
isolate, subsequent cultivation of the bacteria led us to determine that
the culture contained two taxa, which were separated through isolation
on a solid agar medium and analyzed in pure culture.
A single colony of the Serratia sp. was used to inoculate 1/10th
strength tryptic soy broth medium, which, after 16 h, was used to
obtain genomic DNA by means of an Xpedition Soil/Fecal DNA
MiniPrep kit following the manufacturer’s directions (Zymo Research,
Irvine, CA, USA). The genomic DNA was quantiﬁed using the QuBit
BR assay (Life Technologies, Carlsbad, CA, USA), and approximately
1 μg was sheared to a mean insert size of 500 bp and sequenced using
PE250 V2 chemistry on the Illumina MiSeq platform (Illumina, San
Diego, CA, USA).
The reference strain C. albicans SC5314 was cultured in brain-heart
infusion medium (BHI, Becton Dickinson) or RPMI-1640 plus MOPS
medium [RPMI-1640 medium (Sigma) buﬀered to pH 7.0 with 0.17
M MOPS (3-(N-morpholino)propanesulfonic acid, Sigma)] as
required.
Sequence Data for the Serratia sp. Isolate. Sequence data used
for 16S rRNA gene analysis are available at the NCBI SRA under
accession number SRX1601902. The annotated Serratia sp. genome is
available under the accession number GCA_001643155.1, and the raw
reads used to assemble the genome are available for download at the
NCBI SRA under the accession number SRX1585056.
DNA Extraction and 16S rRNA Gene Library Preparation.
The opossum carcass was sampled with sterile cotton swabs, and the
swabs were frozen at −20 °C until DNA extraction was performed.
The samples were thawed and then homogenized (BioSpec Products,
Bartlesville, OK, USA) for 30 s. Community genomic DNA was
extracted using the MoBio Power Bioﬁlm DNA extraction kit (MoBio
Laboratories, Inc., Carlsbad, CA, USA). Libraries of bacterial and
archaeal 16S rRNA gene fragments were ampliﬁed from each DNA
extraction by PCR with primers that spanned the V4 region between
positions 519 and 802 (E. coli numbering), producing a ∼300 bp
fragment. These primers evenly amplify a broad range of both the
Bacteria and Archaea. The forward primer (M13L-519F: 5′-GTA AAA
CGA CGG CCA GCA CMG CCG CGG TAA-3′) contained the M13
forward primer (in bold), followed by the 16S rRNA gene-speciﬁc
sequence (underlined). The reverse primer (785R: 5′-TAC NVG
GGT ATC TAA TCC-3′) was taken directly from “S-D-Bact07850b-
A-18” in Klindworth et al.34 Each 50 μL PCR consisted of 3 U of
recombinant Taq polymerase (Thermo Fisher Scientiﬁc Inc., Grand
Island, NY, USA), 1.5 mM MgCl2, 0.1 μM DNTPs (Thermo Fisher
Scientiﬁc Inc.), 0.2 μM of each primer, and 4 μL of a DNA extraction.
Initial ampliﬁcation was conducted using the following protocol: initial
denaturation at 95 °C for 2 min, followed by 30 cycles of denaturation
at 95 °C for 45 s, annealing at 52 °C for 45 s, and extension at 72 °C
for 45 s, followed by a ﬁnal extension at 72 °C for 5 min. The
ampliﬁed 16S rRNA gene fragments in each library were puriﬁed using
AmpureXP paramagnetic beads according to the manufacturer’s
protocols (Beckman Coulter, Inc., Indianapolis, IN, USA). A second,
six-cycle PCR was used to add a unique 12 bp barcode35 to each
amplicon library using a unique forward primer containing the barcode
+ M13 forward sequence (5′−3′) and the 785R primer using reaction
conditions identical to those listed above. The resulting barcoded PCR
products were quantiﬁed using the QuBit HS assay (Life
Technologies), pooled in equimolar amounts, and concentrated to a
ﬁnal volume of 80 μL using Amicon Ultra-0.5 mL 30K centrifugal
ﬁlters (Merck Millipore Corp., Billerica, MA, USA). The pooled library
was then submitted for sequencing on the MiSeq platform using
PE250 V2 chemistry (Illumina).
Sequence Analysis. After sequencing, reads were merged using
PEAR,36 demultiplexed in QIIME,37 ﬁltered by quality, and clustered
into OTUs using UPARSE.38 The mapping ﬁle used to demultiplex
the samples is present as a supplementary table. The taxonomy of each
OTU was assigned using UCLUST39 and the SILVA database
(Release 123).40 Taxonomy summaries were generated within QIIME.
For the genomic sequence, reads were ﬁrst quality trimmed, and
sequence adapters were removed using PEAT41 before assembly
within SPAdes42 using kmer values of 21, 33, 55, 77, 99, and 127. After
assembly, contiguous sequences less than 300 bp in length were
discarded, and contaminating PhiX sequences were removed after
visualization of the genome assembly graph in Bandage.43 The
assembled genome was annotated using the NCBI PGAP annotation
pipeline, and putative metabolite clusters were identiﬁed using
antiSMASH.44
Deﬁned Medium for Bacterial Growth (DM7). Single colonies
of the Serratia sp. isolate were transferred to DM7 and vortexed.
Aliquots of this suspension were inoculated into 40 high-aeration
shake ﬂasks (2 L Ultra Yield ﬂask) containing 1 L of DM7. The ﬂasks
were shaken at 135 rpm for 7 days at room temperature on an Innova
5000 shaker. The DM7 broth consisted of (per liter) monopotassium
phosphate, 2.0 g; ammonium chloride, 1.5 g; magnesium sulfate
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heptahydrate, 0.5 g; glycerol, 12.6 g; myo-inositol, 0.4 g; monosodium
glutamate, 5.0 g; sodium ﬂuoride, 0.084 g; iron(II) sulfate
heptahydrate, 0.025 g; zinc(II) sulfate heptahydrate, 0.01 g; cobalt(II)
chloride, 0.01 g; calcium carbonate, 0.25 g; and p-aminobenzoate,
0.001 g; with the pH of the ﬁnal solution adjusted to 7.
Crystal Data for 1. The broth from the liquid culture of the
Pseudomonas sp. was partitioned against ethyl acetate. During the
partitioning process, crystals of 1 formed on the inner surface of the
separatory funnel. The crystals were rinsed from the funnel under a
stream of ethyl acetate, and the solvent was removed by leaving the
crystals overnight in an open vial at room temperature.
A colorless needle-shaped crystal of 1 of dimensions 0.26 × 0.04 ×
0.04 mm was selected for structure analysis. Intensity data for this
compound were collected using a diﬀractometer with a Bruker APEX
ccd area detector45,46 and graphite-monochromated Mo Kα radiation
(λ = 1.541 78 Å). The sample was cooled to 100(2) K. Cell parameters
were determined from a nonlinear least-squares ﬁt of 2010 peaks in the
range 4.2° < θ < 68.2°. A total of 39 420 data were measured in the
range of 3.626° < θ < 71.353° using φ and ω oscillation frames. The
data were corrected for absorption by the empirical method47 giving
minimum and maximum transmission factors of 0.835 and 0.972. The
data were merged to form a set of 11 566 independent data with
R(int) = 0.145 and a coverage of 98.5%.
The orthorhombic space group P212121 was determined by
systematic absences and statistical tests and veriﬁed by subsequent
reﬁnement. The structure was solved by direct methods and reﬁned by
full-matrix least-squares methods on F2.48 The positions of hydrogens
bonded to carbons were initially determined by geometry and were
reﬁned using a riding model. Hydrogens bonded to nitrogens and
oxygens were located on a diﬀerence map, and their positions were
reﬁned independently with X-H restraints. Non-hydrogen atoms were
reﬁned with anisotropic displacement parameters. A total of 767
parameters were reﬁned against 51 restraints and 11 566 data to give
wR(F2) = 0.3772 and S = 1.238 for weights of w = 1/[σ2(F2) +
(0.1800P)2 + 30.0000P], where P = [Fo
2 + 2Fc
2]/3. The ﬁnal R(F) was
0.1281 for the 11 016 observed, [F > 4σ(F)] data. The largest shift/s.u.
was 0.000 in the ﬁnal reﬁnement cycle. The ﬁnal diﬀerence map had
maxima and minima of 0.783 and −0.891 e/Å3, respectively. The
absolute conﬁguration of the structure was determined by reﬁnement
of the Flack parameter.49
Puriﬁcation of 2−5. The broth from each culture ﬂask was pooled
and partitioned three times against equal volumes of ethyl acetate. The
solvent was removed in vacuo to generate a crude organic residue (10.3
g). The organic material was processed by VLC over HP20SS resin
using a step gradient going from water to methanol to generate six
fractions. Fraction 4 was further separated by preparative C18 HPLC
(gradient elution with MeOH−H2O, 75:25, to 100% organic in 30
min) to yield three subfractions (1−3). Subfraction 2 was further
separated by semipreparative C18 HPLC (MeCN−H2O, 55:65) to
provide four subfractions (A−D). Subfraction 2C was further puriﬁed
by semipreparative C18 HPLC (MeCN−H2O, 60:40) to yield 2 (46.7
mg, 4.53% yield). Subfraction 2B was further puriﬁed by semi-
preparative C18 HPLC (MeCN−H2O, 65:35) to yield 3 (47.1 mg,
4.57% yield). Subfraction 2A was further puriﬁed by semipreparative
hexyl-phenyl HPLC (MeCN−0.1% formic acid in H2O, 65:35) to
yield 4 (2.8 mg, 0.271% yield) and 5 (3.7 mg, 0.359% yield).
Marfey’s Analysis. Samples of the metabolites (∼300 μg) were
incubated overnight in 6 M HCl (500 μL) at 110 °C. The hydrosylates
were dried under nitrogen gas, and 20 μL of 1 M NaHCO3 was added
to each sample to facilitate neutralization. Next, 100 μL of 1% 1-ﬂuoro-
2,4-dinitrophenyl 5-L-alanine amide was added to the samples, and the
resulting solutions were heated at 45 °C for 1 h. The reaction mixtures
were neutralized with 20 μL of 1 M HCl and diluted with 500 μL of
MeCN. The samples were centrifuged and analyzed by LC-MS (100
Å, C18 Kinetex 2.6 μm, 75 × 3.0 mm column with gradient elution
using MeCN with 0.1% formic acid in H2O, 10:90, to 100% organic
over 15 min.). Standards eluted as L-isoleucine at 7.96 min, D-
isoleucine at 8.19 min, L-valine at 7.68 min, D-valine at 7.68 min, L-
leucine at 7.78 min, D-leucine at 8.26 min, L-phenylalanine at 7.80 min,
D-phenylalanine at 8.13 min, L-serine at 7.57 min, D-serine at 8.13 min,
L-tyrosine at 8.57 min, D-tyrosine at 8.88 min, L-threonine at 8.53 min,
L-allo-threonine at 5.73 min, and D-allo-threonine at 5.90 min.
Examination of 3-Hydroxy Fatty Acids by Polarimetry. The
hydrosylates were partitioned with equal portions of hexanes (×3).
The hexanes were removed in vacuo, the resultant compound was
suspended in 2 mL of chloroform or ethanol, and their speciﬁc
rotation values were determined.
Assays for Growth Inhibition and Bioﬁlm Formation. The
eﬀects of compounds on the growth of C. albicans were tested using
the method described in the NCCLS 2008 CLSI M27-A3 guidelines24
with the following modiﬁcations. Cells of C. albicans SC5314 were
cultured in BHI medium (Becton Dickinson Co., Franklin Lakes, NJ,
USA) at 37 °C overnight. The cells were pelleted by centrifugation,
washed with sterile PBS (pH 7.4), and resuspended in RPMI-1640
plus MOPS medium. Test compounds were prepared in DMSO at
stock concentrations of 2 mM before being diluted in RPMI-1640 plus
MOPS for testing. Aliquots of yeast suspension (100 μL containing 2.5
× 103 cells mL−1) were added to the medium containing the diluted
compounds or DMSO [ﬁnal concentrations did not exceed 2% (v/v)]
before being transferred to 96-well plates (Corning). After 48 h of
incubation at 37 °C, the viability of the yeast was measured using the
XTT assay. In brief, yeast cells were treated with 0.1 mg mL−1 XTT at
37 °C for 1 h. Absorbance measurements were taken at 492 nm using
a microplate reader (Inﬁnite M200). The minimum inhibitor
concentrations (MIC) for growth were deﬁned as the lowest antifungal
concentrations that caused ≥85% reduction in metabolic activity.
For measuring bioﬁlm formation, the medium was aspirated and the
wells were washed twice with sterile PBS to remove nonadherent cells.
Fresh medium (100 μL of RPMI-1640 plus MOPS) was then added
back to each well. The formation of bioﬁlms was measured using the
XTT assay. All experiments were performed in triplicate on three
separate occasions. The 50% inhibitory concentration (IC50) values for
bioﬁlm inhibition were calculated using GraphPad Prism 5.
Serrawettin W2 (2): white, powdery solid; [α]D
20 = −7.3 (c 0.164,
CHCl3); UV (MeOH) λmax (log ε) 206 (3.52); IR (ﬁlm) νmax 3600,
3516, 3412, 3003, 2965, 2926, 1715, 1425, 1362, 1221, 1092, 903, 783,
527; 1H NMR (DMSO-d6, 600 MHz) refer to Table 1;
13C NMR
(DMSO-d6, 151 MHz) refer to Table 2; HRESIMS m/z 730.4402 [M
− H]− (calcd for C38H60N5O9, 730.4391).
Serrawettin W4 (3): white, powdery solid; [α]D
20 = −7.4 (c 0.270,
CHCl3); UV (MeOH) λmax (log ε) 206 (3.17); IR (ﬁlm) νmax 3607,
3524, 3412, 3003, 2967, 2925, 1713, 1707, 1427, 1361, 1221, 1094,
903, 783, 527; 1H NMR (DMSO-d6, 600 MHz) refer to Table 1.
13C
NMR (DMSO-d6, 151 MHz) refer to Table 2; HRESIMS m/z
740.4235 [M + Na]+ (calcd for C37H59N5O9Na, 740.4210).
Serrawettin W5 (4): white, powdery solid; [α]D
20 = −7.6 (c 0.245,
CHCl3); UV (MeOH) λmax (log ε) 204 (3.05); IR (ﬁlm) νmax 3603,
3520, 3412, 3003, 2968, 2926, 1714, 1427, 1362, 1221, 1094, 905, 783,
523; 1H NMR (DMSO-d6, 600 MHz) refer to Table 1.
13C NMR
(DMSO-d6, 151 MHz) refer to Table 2; HRESIMS m/z 726.4073 [M
+ Na]+ (calcd for C36H57N5O9Na, 726.4054).
Serrawettin W6 (5): white, powdery solid; [α]D
20 = −7.4 (c 0.140,
CHCl3); UV (MeOH) λmax (log ε) 206 (3.11); IR (ﬁlm) νmax 3609,
3528, 3412, 3003, 2695, 2924, 1746, 1712, 1422, 1362, 1222, 1092,
903, 785, 530; 1H NMR (DMSO-d6, 600 MHz) refer to Table 1.
13C
NMR (DMSO-d6, 151 MHz) refer to Table 2; HRESIMS m/z
770.4346 [M + Na]+ (calcd for C38H61N5O10Na, 770.4316).
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